k-ras基因突变的定量检测在胰腺疾病诊断中的应用

Quantitative detection of k-ras codon 12 mutation in pancreatic diseases

目的:探讨k-ras基因第12密码子突变的定量检测在胰腺疾病鉴别诊断中的价值及其意义.方法:应用肽核酸钳制实时荧光定量PCR方法检测143例胰腺癌、110例慢性胰腺炎以及28名正常人的血液中k-ras基因第12密码子的突变量,并分析其与相关临床指标的关系.结果:胰腺癌、慢性胰腺炎和正常人血液中k-ras基因的突变阳性率分别为51.75%、37.27%和7.14%.k-ras基因的突变比例分别为0.821%±0.287%、0.200%±0.064%和0.080%±0.056%.慢性胰腺炎和正常人即使存在k-ras突变,其突变比例通常也较胰腺癌低.胰腺癌患者血液的k-ras突变情况与性别、年龄、吸烟、饮酒、肿瘤TNM分期与临床分期无明显相关.结论:肽核酸钳制实时荧光定量PCR方法可用于胰腺疾病的鉴别诊断.

AIM： To evaluate the value of quantitative detection of a k-ras gene mutation at codon 12 in the diagnosis of pancreatic diseases. METHODS： k-ras codon 12 mutation was quantitatively detected by peptide nucleic acid-mediated real-time PCR clamping in blood samples from 143 patients with pancreatic cancer, 110 patients with chronic pancreatitis, and 28 disease-free people. The results were analyzed using SPSS 18.0. RESULTS： The positive rates of k-ras codon 12 mutation in patients with pancreatic cancer, those with chronic pancreatitis and normal disease-free people were 51.75%, 37.27% and 7.14%, respectively. The percentages of k-ras gene mutation in the above three groups of patients were 0.821% ± 0.287%, 0.200% ± 0.064% and 0.080% ± 0.056%, respectively. k-ras codon 12 mutation had no significant correlation with gender, age,smoking, alcohol, TNM stage, and clinical stage in patients with pancreatic cancer. CONCLUSION： Quantitative detection of k-ras codon 12 mutation can be used to distinguish different pancreatic diseases.